Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


18.06.2018

1 AMIA Jt Summits Transl Sci Proc
1 Arab J Urol
1 Biochim Biophys Acta
1 Biomark Med
1 Biomed Pharmacother
1 BMC Cancer
1 Bull Cancer
1 Cancer Treat Rev
1 Clin Genitourin Cancer
1 Clin Oncol (R Coll Radiol)
1 Eur J Radiol
1 Front Physiol
1 Genes Genomics
2 Int J Oncol
1 Iran J Public Health
1 J Cancer Res Ther
1 J Cell Physiol
1 J Obes
1 Lancet Oncol
1 Med Sci Monit
1 Oncotarget
1 Sci Rep
2 Urol Oncol
1 Urologe A
1 Vet J
1 Zhonghua Yi Xue Za Zhi


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AMIA Jt Summits Transl Sci Proc

  1. POIRION OB, Chaudhary K, Garmire LX
    Deep Learning data integration for better risk stratification models of bladder cancer.
    AMIA Jt Summits Transl Sci Proc. 2018;2017:197-206.
    PubMed     Text format     Abstract available


    Arab J Urol

  2. MAZDAK H, Tolou-Ghamari Z
    Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran.
    Arab J Urol. 2018;16:206-210.
    PubMed     Text format     Abstract available


    Biochim Biophys Acta

  3. WEN H, Lee S, Zhu WG, Lee OJ, et al
    Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer.
    Biochim Biophys Acta. 2018 Jun 5. pii: S1388-1981(18)30126.
    PubMed     Text format     Abstract available


    Biomark Med

  4. TOLLE A, Blobel CC, Jung K
    Circulating miRNAs in blood and urine as diagnostic and prognostic biomarkers for bladder cancer: an update in 2017.
    Biomark Med. 2018 Jun 13. doi: 10.2217/bmm-2017-0392.
    PubMed     Text format     Abstract available


    Biomed Pharmacother

  5. LI Z, Lin C, Zhao L, Zhou L, et al
    Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer.
    Biomed Pharmacother. 2018;105:461-469.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. LIU Y, Wang H, Zhong J, Wu C, et al
    Decreased expression of SRY-box containing gene 30 is related to malignant phenotypes of human bladder cancer and correlates with poor prognosis.
    BMC Cancer. 2018;18:642.
    PubMed     Text format     Abstract available


    Bull Cancer

  7. MARINONI F, Destro F, Selvaggio GGO, Riccipetitoni G, et al
    Urothelial carcinoma in children: A case series.
    Bull Cancer. 2018;105:556-561.
    PubMed     Text format     Abstract available


    Cancer Treat Rev

  8. TAN WS, Tan WP, Tan MY, Khetrapal P, et al
    Novel urinary biomarkers for the detection of bladder cancer: A systematic review.
    Cancer Treat Rev. 2018;69:39-52.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  9. BOSSCHIETER J, Hentschel A, Savci-Heijink CD, Patrick van der Voorn J, et al
    Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder Tumors.
    Clin Genitourin Cancer. 2018 May 11. pii: S1558-7673(18)30196.
    PubMed     Text format     Abstract available


    Clin Oncol (R Coll Radiol)

  10. JENA R
    Bladder Cancer Virtual Special Issue.
    Clin Oncol (R Coll Radiol). 2018 Jun 5. pii: S0936-6555(18)30276.
    PubMed     Text format    


    Eur J Radiol

  11. HARTMAN R, Kawashima A
    Lower tract neoplasm: Update of imaging evaluation.
    Eur J Radiol. 2017 Nov 1. pii: S0720-048X(17)30415.
    PubMed     Text format     Abstract available


    Front Physiol

  12. SU G, He Q, Wang J
    Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review.
    Front Physiol. 2018;9:652.
    PubMed     Text format     Abstract available


    Genes Genomics

  13. YANG J, Li W, Zhang Z, Shen J, et al
    PSCArs2294008 T polymorphism increases the risk of bladder cancer in Bai, Dai, and Han ethnicity in China and a potential mechanism.
    Genes Genomics. 2018;40:531-541.
    PubMed     Text format     Abstract available


    Int J Oncol

  14. ZHANG L, Yang G, Zhang R, Dong L, et al
    Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells.
    Int J Oncol. 2018 May 30. doi: 10.3892/ijo.2018.4423.
    PubMed     Text format     Abstract available

  15. SUGITA S, Enokida H, Yoshino H, Miyamoto K, et al
    HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
    Int J Oncol. 2018 Jun 11. doi: 10.3892/ijo.2018.4435.
    PubMed     Text format     Abstract available


    Iran J Public Health

  16. RASHIDIAN H, Zendehdel K, Daroudi R, Ebadzadeh MR, et al
    Epidemiology and Hospitalization Cost of Bladder Cancer in Kerman Province, Southeastern Iran.
    Iran J Public Health. 2018;47:567-574.
    PubMed     Text format     Abstract available


    J Cancer Res Ther

  17. RAFIEMANESH H, Lotfi Z, Bakhtazad S, Ghoncheh M, et al
    The epidemiological and histological trend of bladder cancer in Iran.
    J Cancer Res Ther. 2018;14:532-536.
    PubMed     Text format     Abstract available


    J Cell Physiol

  18. ZO RB, Long Z
    MiR-124-3p suppresses bladder cancer by targeting DNA methyltransferase 3B.
    J Cell Physiol. 2018 Jun 12. doi: 10.1002/jcp.26591.
    PubMed     Text format     Abstract available


    J Obes

  19. HARIHARAN N, Ashcraft KA, Svatek RS, Livi CB, et al
    Adipose Tissue-Secreted Factors Alter Bladder Cancer Cell Migration.
    J Obes. 2018;2018:9247864.
    PubMed     Text format     Abstract available


    Lancet Oncol

  20. GOURD E
    EMA restricts use of anti-PD-1 drugs for bladder cancer.
    Lancet Oncol. 2018 Jun 7. pii: S1470-2045(18)30433.
    PubMed     Text format    


    Med Sci Monit

  21. WANG Z, Li H, Chi Q, Qiu Y, et al
    Clinical Significance of Serological and Urological Levels of Bladder Cancer-Specific Antigen-1 (BLCA-1) in Bladder Cancer.
    Med Sci Monit. 2018;24:3882-3887.
    PubMed     Text format     Abstract available


    Oncotarget

  22. RINALDETTI S, Rempel E, Worst TS, Eckstein M, et al
    Subclassification, survival prediction and drug target analyses of chemotherapy-naive muscle-invasive bladder cancer with a molecular screening.
    Oncotarget. 2018;9:25935-25945.
    PubMed     Text format     Abstract available


    Sci Rep

  23. CHEN Y, Li W, Zeng Z, Tang Y, et al
    (-)-Gochnatiolide B, synthesized from dehydrocostuslactone, exhibits potent anti-bladder cancer activity in vitro and in vivo.
    Sci Rep. 2018;8:8807.
    PubMed     Text format     Abstract available


    Urol Oncol

  24. FRANSEN VAN DE PUTTE EE, Otto W, Hartmann A, Bertz S, et al
    Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.
    Urol Oncol. 2018 Jun 4. pii: S1078-1439(18)30159.
    PubMed     Text format     Abstract available

  25. VARTOLOMEI MD, Porav-Hodade D, Ferro M, Mathieu R, et al
    Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
    Urol Oncol. 2018 Jun 5. pii: S1078-1439(18)30166.
    PubMed     Text format     Abstract available


    Urologe A

  26. RETZ M, Karl A
    [Bladder cancer : Current diagnosis and treatment modalities].
    Urologe A. 2018;57:655-656.
    PubMed     Text format    


    Vet J

  27. HONKISZ SI, Naughton JF, Weng HY, Fourez LM, et al
    Evaluation of two-dimensional ultrasonography and computed tomography in the mapping and measuring of canine urinary bladder tumors.
    Vet J. 2018;232:23-26.
    PubMed     Text format     Abstract available


    Zhonghua Yi Xue Za Zhi

  28. WANG JF, Zhou XF, Fang DB, Wu ZM, et al
    [The effect of tri-modality therapy on the treatment of muscle-invasive bladder cancer].
    Zhonghua Yi Xue Za Zhi. 2018;98:1614-1616.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: